المؤلفون: Scheel, Andreas H., Ansen, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael, Stoelben, Erich, Groen, Harry, Timens, Wim, Perner, Sven, von Bergwelt-Baildon, Michael, Buettner, Reinhard, Wolf, Juergen

المصدر: Scheel , A H , Ansen , S , Schultheis , A M , Scheffler , M , Fischer , R N , Michels , S , Hellmich , M , George , J , Zander , T , Brockmann , M , Stoelben , E , Groen , H , Timens , W , Perner , S , von Bergwelt-Baildon , M , Buettner , R & Wolf , J 2016 , ' PD-L1 expression in non-small cell lung cancer : Correlations with genetic alterations ' , OncoImmunology , vol. 5 , no. 5 , 1131379 . https://doi.org/10.1080/2162402X.2015.1131379Test

مصطلحات موضوعية: Checkpoint inhibition, early stage NSCLC, genetic alterations, immunohistochemistry, non-small cell lung cancer, PD-L1, 5H1, DEATH-LIGAND 1, ANTIBODY MPDL3280A, BREAST-CANCER, NIVOLUMAB, MELANOMA, IMMUNE, TUMOR, B7-H1, ADENOCARCINOMA, PEMBROLIZUMAB

العلاقة: https://research.rug.nl/en/publications/45183bcf-9331-4a75-bb12-06f86907305bTest

الإتاحة: https://doi.org/10.1080/2162402X.2015.1131379Test
https://hdl.handle.net/11370/45183bcf-9331-4a75-bb12-06f86907305bTest
https://research.rug.nl/en/publications/45183bcf-9331-4a75-bb12-06f86907305bTest

المؤلفون: Juergen Wolf, Rieke Fischer, Michael Brockmann, Thomas Zander, Julie George, Sascha Ansén, Wim Timens, Michael von Bergwelt-Baildon, Anne M. Schultheis, Erich Stoelben, Matthias Scheffler, Reinhard Buettner, Harry J.M. Groen, Andreas H. Scheel, Sven Perner, Sebastian Michels, Martin Hellmich

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Groningen Research Institute for Asthma and COPD (GRIAC)

المصدر: OncoImmunology, 5(5):1131379. Taylor & Francis Group

مصطلحات موضوعية: 0301 basic medicine, Oncology, PD-L1, medicine.medical_specialty, early stage NSCLC, DEATH-LIGAND 1, medicine.medical_treatment, Immunology, IMMUNE, MELANOMA, Pembrolizumab, Biology, medicine.disease_cause, ANTIBODY MPDL3280A, 03 medical and health sciences, 5H1, 0302 clinical medicine, TUMOR, Internal medicine, Checkpoint inhibition, medicine, Immunology and Allergy, BREAST-CANCER, Lung cancer, PEMBROLIZUMAB, non-small cell lung cancer, Original Research, genetic alterations, Melanoma, NIVOLUMAB, ADENOCARCINOMA, Immunotherapy, medicine.disease, B7-H1, 030104 developmental biology, 030220 oncology & carcinogenesis, immunohistochemistry, Cancer research, biology.protein, Adenocarcinoma, KRAS, Antibody

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4fe71ef809691242aa09ab32f1d86cfTest
https://research.rug.nl/en/publications/45183bcf-9331-4a75-bb12-06f86907305bTest